Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Sentiment AnalystBuy
Sentiment Score8/10
Generated At:2026-04-18 00:00:00
Analysis based on 20 news articles published between April 15-17, 2026. Primary sources include official company announcements (Q1 earnings, dividend), analyst research reports from Barclays, Morgan Stanley, and Bank of America, and financial news coverage from Yahoo Finance (via MT Newswires, Zacks). Data timeliness is excellent, with core catalysts being less than 24-72 hours old. The narrative is consistent across multiple credible sources.
News Overview

The news impact on JNJ's price is strongly positive, with an expected short-term upside of 4.5% to 6.6% to the $245-$250 range and a medium-term target of $255. The combination of fundamental strength, analyst endorsements, and long-term growth targets enhances the investment case. Recommendation: Buy/Accumulate for existing holders and consider initiation for new investors.

Positive
5
Neutral
0
Negative
0
Event Timeline
2026-04-17
Price Impact: +5% to +9% (to $245-$255 range)
short-term to medium-term
Major financial institutions have issued bullish updates on JNJ. On April 17, 2026, Barclays increased its price target to $255, a significant raise from $234, directly attributing it to strong pharmaceutical momentum. Simultaneously, Morgan Stanley published a note reinforcing the positive momentum story, countering notions that the stock's recent outperformance is fully priced in. These actions provide clear, quantifiable near-term price objectives and institutional endorsement.
2026-04-17
Price Impact: +5% to +10%
long-term
JNJ's management has provided clear long-term financial targets, aiming to hit $100 billion in revenue for the full year 2026 and targeting double-digit growth by 2030. This strategic roadmap offers investors significant long-term visibility and confidence. While the plan acknowledges challenges such as biosimilar competition for the drug Stelara, the focus is on executing a pivot to higher-growth therapies in Innovative Medicine and MedTech to achieve these goals.
2026-04-17
Price Impact: +1% to +2%
short-term
The positive news flow for JNJ coincides with a strongly supportive macro environment. On April 17, 2026, the broader market rallied sharply, with the Dow Jones Industrial Average jumping 800 points (1.79%) and the S&P 500 hitting a new record. This strong market tailwind creates a favorable backdrop that can amplify the impact of JNJ's company-specific positive catalysts.
2026-04-16
Price Impact: +2% to +4%
long-term
Multiple articles from April 16-17, 2026, reinforce JNJ's perception as a high-quality, defensive asset. It is celebrated as a 'Dividend King' with a 64-year growth streak, now being re-framed as a 'growth machine.' It is also listed among healthcare stocks that historically perform well during market downturns. This narrative enhances its appeal as both an income-generating and safe-haven investment, particularly relevant in volatile or inflationary market environments.
2026-04-15
Price Impact: +3% to +5%
medium-term to long-term
JNJ's Q1 2026 results, reported on April 15-16, 2026, showed fundamental strength with sales of $24.06 billion and net income of $5.24 billion, characterized as 'above-peer top-line growth.' Concurrently, the board approved a 3.1% dividend increase to $1.34 per share, extending its legendary dividend growth streak to 64 consecutive years. This powerful combination of operational performance and shareholder return is a core positive catalyst.
News Topics List

Barclays Raises Price Target on Strong Pharma Momentum

2026-04-17positivePrice Impact: +5% to +9% (to $245-$255 range)short-term to medium-term
AI Key Summary
  • Barclays raised its price target for JNJ to $255 from $234.
  • The increase is directly attributed to 'Strong Pharma Momentum.'
  • This action provides a clear, quantifiable near-term price objective from a major financial institution.
  • The news is highly timely, being less than 24 hours old at the time of analysis, making it highly relevant for immediate market sentiment.
Source

Strong Q1 2026 Earnings and 64th Consecutive Dividend Hike

2026-04-15positivePrice Impact: +3% to +5%medium-term to long-term
AI Key Summary
  • JNJ reported Q1 2026 sales of $24.06 billion and net income of $5.24 billion.
  • The results demonstrated 'above-peer top-line growth.'
  • Concurrently, the board approved a 3.1% dividend increase to $1.34 per share.
  • This marks the company's 64th consecutive year of dividend growth, reinforcing its status as a 'Dividend King.'
  • The combination of operational strength and shareholder return is a powerful fundamental catalyst.
Source

Morgan Stanley Bullish Commentary on Continued Momentum

2026-04-17positivePrice Impact: +5% to +10%medium-term
AI Key Summary
  • Morgan Stanley published a note suggesting JNJ 'may still have room to run.'
  • This view comes despite the stock being up approximately 55% over the past year.
  • The commentary reinforces the positive momentum story and counters the notion that recent outperformance is fully priced in.
  • It adds to the chorus of bullish analyst sentiment surrounding the stock.
Source

JNJ's Long-Term Growth Targets: $100B in 2026, Double-Digit by 2030

2026-04-17positivePrice Impact: +2% to +4%long-term
AI Key Summary
  • Management has laid out a plan to reach $100 billion in revenue in the full year 2026.
  • The company is targeting double-digit growth by 2030.
  • These targets provide long-term visibility and confidence for investors.
  • The strategy acknowledges headwinds like biosimilar competition for Stelara but focuses on offsetting them with new drug launches.
  • The 2030 growth target provides a clear strategic roadmap.
Source

Re-framing as a Defensive 'Dividend King' and Growth Machine

2026-04-16positivePrice Impact: +1% to +2%long-term
AI Key Summary
  • Multiple articles highlight JNJ as a 'Dividend King' and a 'boring' stock turning into a 'growth machine.'
  • It is cited as one of the healthcare stocks that holds up best during market downturns, strengthening its safe-haven appeal.
  • This narrative enhances its attractiveness as both an income-generating and defensive asset.
  • The framing is particularly relevant in the context of noted market volatility and inflation fears.
Source